59 results
8-K
EX-10.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
, importation, exportation, handling, quality, safety, surveillance, reporting of adverse events and product complaints, recall, reprocessing … nor any member of the TXMD Group has, of its own accord or at the request of any Regulatory Authority initiated, conducted, or issued a recall, market
8-K
EX-10.1
ucoqbuvoay
31 Oct 22
TherapeuticsMD Announces Additional $7 Million Private Placement
7:00am
8-K
EX-10.1
6vff3t
3 Oct 22
TherapeuticsMD Announces $7 Million Private Placement
7:00am
8-K
EX-10.1
k0b5w0er2o
1 Aug 22
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
6:55am
8-K
EX-10.2
jgsdbr5 4mjp
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
8-K
EX-2.1
sw7tly9f
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
8-K
EX-2.1
s8asc2rf 54yk33btp
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
S-3ASR
EX-1.2
rxxltk
4 Mar 21
Automatic shelf registration
12:00am
8-K
EX-1.1
qec0d082
16 Feb 21
Entry into a Material Definitive Agreement
8:35am
8-K
EX-1.1
brii6w
27 Nov 20
Entry into a Material Definitive Agreement
4:35pm
8-K
EX-1.1
udbonwxyq guutrx
13 Nov 20
Entry into a Material Definitive Agreement
12:00am